Search

Your search keyword '"Schultz, Andre"' showing total 193 results

Search Constraints

Start Over You searched for: Author "Schultz, Andre" Remove constraint Author: "Schultz, Andre"
193 results on '"Schultz, Andre"'

Search Results

2. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

6. Inferring gene expression from cell-free DNA fragmentation profiles

7. Survival of people with cystic fibrosis in Australia

9. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

10. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily

11. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

12. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

17. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis.

19. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

20. Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial

21. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia

26. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

27. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia.

30. Abstract 3375: Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq

33. Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

34. MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

35. Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

36. Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

37. Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

38. Survival of People with Cystic Fibrosis in Australia

39. Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis

40. Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial

42. Prevalence of Chronic Respiratory Diseases in Aboriginal Children: A Whole Population Study

44. List of Contributors

45. Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

47. Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial

49. End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Catalog

Books, media, physical & digital resources